Sensorium Therapeutics Closes $30 Million Series A to Transform Mental Health Treatment with Nature-Inspired Psychoactive Medicines – QNT Press Release


Human-first Biodynamic Discovery Platform™ employs cutting-edge chemistry, neuroscience, and machine learning to advance plant- and fungi-inspired therapeutics to address global crisis

The Company’s scientific founders include leading experts in neuroscience, chemistry, and psychiatry

Financing led by Santé Ventures, Route 66 Ventures, and CU Healthcare Innovation Fund

BOSTON, Nov. 8, 2022 /PRNewswire/ — Sensorium Therapeutics (Sensorium), a biotechnology company leveraging medicinal chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for mental health, today announced the closing of a $30 million Series A financing to advance its initial asset, SENS-01, and Biodynamic Discovery Platform™ (BDP), a drug discovery engine that rapidly identifies, synthesizes, and enhances targeted molecules as novel therapeutics. The round was led by Santé Ventures, a specialized healthcare and life sciences investment firm with approximately $1 billion in capital under management, with participation from Route 66 Ventures, CU Healthcare Innovation Fund, WPSS.bio, Palo Santo, Iter Investments, Ocama Partners, and re.Mind Capital.

“To address this devastating mental health crisis, we urgently need to broaden the universe of safe and effective treatments by …

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center